The Initial Public Offering (IPO) is a necessary element of the emerging growth ecosystem.
IPO's represent the pinnacle of the growth capital continuum. The goal. IPO's offer the most efficient access to capital in the most liquid environment at the highest valuation. A robust IPO market expands private financing and strengthens "Exit" pathways, while maximizing returns for shareholders and management.
However, according to a 2015 study by Grant Thornton, the market for underwritten IPO's in the U.S. is closed to 80% of the companies that need it. Notwithstanding occasional resurgence in IPO activity, the number of listed companies in the U.S. has declined by 55% since 1999 to (5,401). In 2015, only (6) out of (66) IPO's raised less than $50 million, while the number of underwriters completing $25 to $50 million IPO's has declined to (31) from (162) in 2002.
Healthios is changing the story for public companies, by:
- Re-inventing the IPO
- Making the IPO relevant for growth companies
- Maximizing financing options at the pre-IPO and IPO stage
- Optimizing alignment of interests among public and private shareholders
- Enhancing liquidity and exit alternatives at the most ideal valuations